Prasad V*, Rajkumar V.  Conflict of Interest in Hematology Oncology.  BCJ

Mailankody S, Prasad V*.  Overall survival:  A new surrogate endpoint? JAMA Oncology

Tao D, Boothby A, Louth J, Prasad V*. Financial COI among Hematologist Oncologists on Twitter. JAMA Internal Medicine  

Mailankody S, Prasad V. The High Cost of Cancer Drugs: Origins, Harms, Barriers Solutions. Nature Reviews Clinical Oncology

De Jesus K, Prasad V*.  Closed financial loops: When it happens in Government It is Called Corruption; When it Happens in Medicine It's just a Footnote. Hasting Center Report

Gyawali B, Prasad V* Drugs that Lack Single Agent Activity:  Do they work? Are they worth pursuing? Nature Reviews Clinical Oncology

Prasad V*. How the USPSTF's Mammographic Screening Guidelines Should Be Interpreted. AJM.

Mailankody S, Prasad V*.  Drug company promotion in era of unprecidented advertisement. JAMA

Lammers A, Edmiston J, Kaestner V, Prasad V*. Financial Conflict of Interest and Academic Influence among Expert Speakers on Behalf of the Pharmaceutical Industry at the US Food and Drug Administration’s Oncology Drug Advisory Committee:  An Analysis of 5 Years of Meetings (2011-2015). Mayo Clinic Proceedings

Gyawali B, Prasad V*.  Combining drugs and extending treatment: Two instances where PFS is not enough.  Nature Reviews Clinical Oncology

Gyawali B, Prasad V*. The billion-dollar subgroup analysis: Pemetrexed in the treatment of non small cell lung cancer.

Goldstein D, Bilal U, Prasad V. Censoring with Pembrolizumab. Cancer

Gyawali B, Prasad V*.  Health policy: Me-too drugs with limited benefits — the tale of regorafenib for HCC. Nature Reviews Clinical Oncology.

Kaestner V, Brown A, Tao D, Prasad V*. Hematologist Oncologists tweet about drugs from companies that compensate them without disclosing the conflict.

Kemp R, Prasad V*. Surrogate Endpoints in Oncology: When are they acceptable for regulatory and clinical decisions? And, are they currently overused? BMC Medicine

Kaestner V, Prasad V. Availability of Jobs in Oncology is 45 fold greater than Medical specialties. Blood Cancer Journal.



Dhruva S, Prasad V*.  Paying for Blinotumomab.  JAMA Oncology 

Prasad V*, Lenzer J, Newman D.  Why cancer screening has never been shown to 'save lives'.  BMJ (In Press)

Abola M, Prasad V*. Characteristics and Conflicts Among Public Speakers at the ODAC.  JAMA Internal Medicine 

- Covered in Lancet Oncology: Oncology Drug Advisory Committee and Conflicts of Interest

-Also covered in Nature Reviews Clinical Oncology. Health policy: Addressing conflicts of interest of public speakers at advisory committee meetings

Massey P, Wang R, Prasad V, Bates S, Fojo T.  Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting in Peer-Reviewed Journals. The Oncologist 

Prasad V, Fojo T, Brada M. The origins and optimism of precision oncology and radiotherapy and what it will take to live up to the promise. Lancet Oncology

Prasad V*. How should research be funded?  Difficulties with the argument for proportionality to causes of death or years of life lost? JNCCN

Kim C, Prasad V*.  Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration’s Approval of Oncology Drugs. Mayo Clinic Proceedings 

Mailankody S, Prasad V*. Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. Oncologist. 

Vandross A, Prasad V*, Mailankody S. ASCO Plenary Sessions: Impact, Legacy, Future. Seminars In Oncology.

Mailankody S, Prasad V*. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices.  JAMA.

Prasad V, Mailankody S. The United Kingdom’s Cancer Drug Fund Experiment and the United States’ Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs until It is Unbearable. Mayo Clinic Proceedings

Boothby A, Wang R, Cetnar J, Prasad V*. Information Overload and ASCO's 2015 Financial COI disclosure.  JAMA Oncology.

Prasad V*.  Is Prostate Cancer Screening Responsible for the Negative Results of Prostate Cancer Treatment Trials? Medical Hypotheses.

Parikh R, Prasad V*.  Blood based testing for colon cancer:  A disruptive innovation or simply a disruption.  JAMA.

Beer T, Prasad V.  Taking Care of Our Friends and Neighbors:  Comment on Vincent DeVita's Death of Cancer. JAMA Oncology.

Gyawali B, Prasad V*. Same data, different interpretation. JCO.

Prasad V,* Gale RPG. Precision Medicine in Acute Myeloid Leukemia: Hope, Hype or Both. Leukemia Research.

Prasad V, Wang R, Affis A, Mailankody S. The Rising Price of Cancer Drugs: A New Old Problem?  JAMA Oncoilogy.  

Abola M, Prasad V*. Financial Conflict of Interest Among Patient Advocacy Groups. Mayo Clinic Proceedings

Bien J, Prasad V*.  Future Jobs of FDA hematology oncology reviewers.  BMJ

Prasad V*.  Precision Medicine in Diffuse Large B Cell Lymphoma:  Hope or Hype? EJC.



Goldstein J, Prasad V.  Disease specific productivity of American cancer hospitals. PLOS One. DOI: 10.1371/journal.pone.0121233

Mailankody S, Prasad V*.  5 year of cancer drugs:  Innovation, Efficacy and Costs.  JAMA Oncol. 2015 Jul 1;1(4):539-40

Prasad V*, Diener-West M. Chemoprevention for breast cancer:  Is it worth it?  CMAJ. 2015 Jun 16;187(9):E276-8.

Burotto M, Prasad V, Fojo T. Problems with non-inferiority trials and why oncologists must remain wary. Lancet Oncol. 2015 Apr;16(4):364-6.

Burotto M, Prasad V.  Emphasizing Unique Strengths and Eliminating Redundancy for Research in Low and Middle Income Countries:  Lessons from a South American Country.  Cancer (In Press)

Prasad V*, Kim C, Burotto M, Vandross V.  Strength of Evidence Between Surrogate Endpoints and Survival in Oncology.  JAMA Internal Medicine (Online First).

         - This article was featured in JAMA Oncology: LeBlanc M, Tangen C. Surrogates for          Survival or Other Endpoints in Oncology. JAMA Oncology (Online First)

Prasad V*, Oseran A.  Do we need randomized trials for rare diseases?  European Journal of Cancer. Eur J Cancer. 2015 Jul;51(11):1355-7.

Jawed I, Wilkerson J, Prasad V, Duffy A, Fojo T. Novel regimens cannot fully account for gains in colorectal cancer survival: An analysis of two decades of colorectal cancer therapy. JAMA Oncology (Online First)

Prasad V*, Berger V. Hard-Wired Bias: How Even Double-Blind Randomized Controlled Trials Can Be Skewed from the Start. Mayo Clinic Proceedings (in Press)

Massey P, Prasad V, Figg WD, Fojo T. Multiplying Therapies and Reducing Toxicity in Multiple Myeloma. Cancer Biol Ther. 2015 May 27:0.

Thomas A, Chen Y, Yu T, Gill A, Prasad V*. Distinctive Characteristics of Malignant Mesothelioma in Young Patients.  Oncotarget.  (In Press)

Prasad V*, Bilal U. The Role of Censoring on Progression Free Survival:  Oncologist Discretion Advised. Eur J Cancer. 2015 Aug 7.

Prasad V*, Goldstein J. Clinical trial spots for cancer patients by tumor type:   The cancer trials portfolio at Clinicaltrials.gov. Eur J Cancer (In Press)

Prasad V*. Non-invasive, serum DNA pregnancy testing leading to incidental discovery of cancer: A good thing? Eur J Cancer. 2015 Aug 13. pii: S0959-8049(15)00709-1.

Prasad V*. Prostate Cancer Screening—The Pendulum has Swung, and the Burden of Proof Now Rests with Proponents. AFP. (In Press)

Abola M, Prasad V*. The Use of Superlatives In Cancer Research JAMA Onc. (In Press)

Prasad V*. Translation Failure and Medical Reversal:  Two Sides to the Same Coin. EJC (In Press)

Prasad V*, Vandross A.  Characteristics of Exceptional or Super Responders to Cancer Drugs. Mayo Clinic Proceedings. (In Press)

Prasad V, Mailankody S. How Should We Assess the Value of Innovative Drugs in Oncology? Lessons from Cost-effectiveness Analyses. Blood October 8, 2015 vol. 126 no. 15 1860-1861

Kim C, Prasad V*.  Cancer Drugs Approved on the Basis of a Surrogate Endpoint and Subsequent Overall Survival.  JAMA Internal Medicine. (In Press)

Prasad V*, Fakhrejahani F, Oseran A. The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary;  Does it also improve survival?  (In Press)

Prasad V, Kumar H, Mailankody S. The Ethics of Clinical Trials in the Low Resource Settings: Lessons from Recent Trials in Cancer Medicine.  Journal of Global Oncology (In Press)

Mailankody S, Prasad V*. Susan Bates, M.D., and Antonio “Tito” Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National
Cancer Institute
.  The Oncologist.  (Online First)

Vaduganathan M, Prasad V. Cardiovascular Risk Assessment in Oncologic Clinical Trials: Is There a Role for Centralized Events Adjudication? European Journal of Heart Failure (In Press)



Prasad V, Mailankody S.  The Accelerated Approval of Oncology Drugs:  Lessons from Ponatinib. JAMA. 2014 Jan 22-29;311(4):353-4.

Prasad V*, Vandross A.  Failing to improve overall survival because post-protocol survival is long:  fact, myth, excuse, or faulty study design? J Cancer Res Clin Oncol. 2014 Apr;140(4):521-4.

Prasad V.*  Balloon breast brachytherapy:  Prove that it works? Or prove that it doesn’t?  J Cancer Res Clin Oncol. 2014 Aug;140(8):1353-7.

Prasad V*. Use of the word cure in the oncology literature. Am J Hosp Palliat Care. (Online First)

Prasad V*, Massey P, Fojo T.  Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients. J Clin Oncol. 2014 May 20;32(15):1620-9.

Mailankody S, Prasad V.*  Comparative Effectiveness Questions in Oncology.  N Engl J Med. 2014 Apr 17;370(16):1478-81.

Prasad V*.  Time to Stop Screening for Prostate Cancer with the PSA test.  JAMA Internal Medicine. (Online First)

Abola M, Prasad V, Jena A. Association between treatment toxicity and outcomes in oncology clinical trials.  Annals of Oncology. 2014 Nov;25(11):2284-9.

Prasad V,* Goldstein JA.  US News and World Report Cancer Hospital Rankings: Do they reflect measures of research productivity? PLOS One. 2014 Sep 23;9(9):e107803.

Prasad V*  Cost considerations in SOFT-TEXT. N Engl J Med. 2014 Oct 2;371(14):1358.

Prasad V*.  The Withdrawal of Drugs for Commercial Reasons:  The Case of Tositumomab, An Incomplete Story JAMA Intern Med. 2014 Dec;174(12):1887-8. 

Vadugnathan M, Prasad V*. Modern Drug Development:  Which Patients Should Come First?  JAMA. 2014 Dec 24-31;312(24):2619-20.


Prasad V*.  Double-crossed:  Why crossover in clinical trials may be distorting medical science. J Natl Compr Canc Netw. 2013 May 1;11(5):625-7.

Ho N, Kim J, Prasad V*.  Dense Breasts and Legislating Medicine. Cleve Clin J Med. 2013 Dec;80(12):768-70. . (See Accompanying Editorial)

Prasad V, Grady C. The Misguided Ethics of Crossover in Randomized Trials.  Contemp Clin Trials. 2013 Dec 21;37(2):167-169


*corresponding author